Friday 13th August 2004 |
Text too small? |
One company with loads of groundbreaking research behind it; a ton of potential but no actual earnings is Pacific Edge Biotechnology.
Pacific Edge has been developing products for cancer treatment, an area of research where progress can be measured in years.
The shares have jumped up and down a bit lately on news that the company is close to signing a breakthrough deal with a Japanese pharmaceutical company, which could offer multimillion-dollar investment.
This is pretty good news because at balance date in March the company's capital was $9.62 million, accumulated deficit was $7.09 million, leaving shareholders' equity of $2.52 million.
That has since been boosted by a private placement of six million shares, raised by brokers Forsyth Barr.
But the company is burning through $1.4 million a year, according to chairman Trevor Scott.
If the Japanese deal goes through, and the company is negotiating with two other firms there as well, Pacific Edge could secure development work for at least four years and be able to fund more oncology tests.
The company, based near the University of Otago, has developed an extensive oncology database to correlate clinical information on cancer progression.
No comments yet
NZAS Sign Long Term Contracts
Amended - IFT230 Maturity and Exchange for IFT350
Synlait forecast milk price update
Chorus submits 2023 fibre regulatory report
Infratil Infrastructure Bond Exchange Offer opens
May 31st Morning Report
NZAS and Mercury sign long-term agreement, creating opportunity for future investment in renewables
Meridian and NZAS sign long term contracts
ArborGen Holdings Results for Year Ended 31 March 2024
BAI - Full unaudited results to 31 March 2024